WASHINGTON — A new clinical diagnostic support tool may help clinicians make more accurate diagnosis of neurocognitive diseases, including Alzheimer’s.
Marie Brunn, PhD, of the Danish Dementia Research Centre, Copenhagen University Hospital, Rigshospitalet, Denmark, and colleagues are conducting a study to determine the accuracy of the PredictND tool in a mixed memory clinic population, according to a poster presentation at the Alzheimer’s Association International Conference 2015.
They plan to enroll at total of 800 patients suspected of having a neurodegenerative disease. They will undergo a clinical examination, neuropsychological assessment, and MRI. All data compiled will be entered into the PredictND tool for analysis. For example, the application will be used to extract imaging biomarkers, as well as visualize data in segmented and analyzed form.
For each participant, a diagnosis and confidence in diagnosis will be made by clinicians with and without PredictND. A follow-up diagnosis after a year will be considered the “gold standard diagnosis.”
The primary outcome will be the change in diagnostic accuracy at baseline with and without PredictND in regards to the 12-month follow-up diagnosis.
“By analyzing and displaying clinical data including imaging biomarkers in a clear and concise manner, it is expected that the PredictND tool will be able to improve the confidence and accuracy of the differential diagnostic of neurodegenerative diseases.
- Bruun M et al. Abstract #3488. A prospective validation study of the PredictND tool — a diagnostic support tool: Rationale and design of the study. Presented at: Alzheimer’s Association International Conference 2015; July 18-23, 2015; Washington, D.C.
This article originally appeared on Psychiatry Advisor